Observational Study of Rebismart®2.0 + MSdialog™ in Subjects With Remitting Multiple Sclerosis (ADHERQOL)

Launched by MERCK KGAA, DARMSTADT, GERMANY · Mar 16, 2015

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosed with RRMS according to McDonald criteria 2010
• • Relapse free within 30 days before Baseline data collection
• • Treatment with Rebif for 6 months or more prior to informed consent
• • Already using RebiSmart®2.0 + MSdialog™ for patient reported outcome (PRO) assessments (at least once prior to informed consent)
• • Females of childbearing potential must be willing to use appropriate contraception for the duration of the study
• • EDSS score less than (\<) 6
• • Written informed consent obtained prior to any protocol-required data collection
• Exclusion Criteria:
• • Participation in other studies within 30 days before Baseline
• • Female who is pregnant or breast feeding
• • Significant psychiatric symptoms that, in the opinion of the Investigator, would impact subject ability to comply with treatment (as per standard clinical practice)
• • Any contraindication for Interferon (IFN) beta-1a therapy as per Summary of Product Characteristics (SPC)
• • Administration of any Multiple Sclerosis (MS) therapy, other than Rebif, within 6 months prior to informed consent